RNA Takeover?

In case you haven’t noticed, my colleague and so-called-friend Anna Rose Welch , editorial and community director at Advancing RNA, has been attempting a sometimes-hostile takeover of the Business of Biotech podcast.

Anna Rose has co-hosted (more like hijacked) several recent episodes. It started with #199 featuring Orna Therapeutics CEO Tom Barnes , Ph.D. Then she got real aggressive, crashing back-to-back parties on #216 with Radar Therapeutics founders Eerik Kaseniit , Ph.D. and Sophia Lugo and #217 with Circio Holding ASA Erik Digman Wiklund . Next month, she’ll again make her intentions known on episodes 224 and 225, a two-part series with former Moderna CMO and current Exsilio Therapeutics CEO Tal Zaks , M.D.

Truth be told, these episodes, all of them featuring builders of RNA therapeutics businesses, have been among my favorite. Anna Rose will likely join me on all RNA-focused episodes moving forward. But don’t worry, I’m effectively defending an all-out RNA takeover. And despite her propensity to geek out over the science, there’s a ton of value in these episodes for biotech builders in any modality.

Make sure you give those episodes a listen, and let me know what you think. In the meantime, here are some recent biotech business content highlights from around the Life Science Connect horn and a few of my favorite quotes from recent guests.

Enjoy!

Matthew Pillar , Business of Biotech host and chief editor, Bioprocess Online

Biotech Beat

Putting The AI in Sanofi

Don’t tell Sanofi ’s Miguelina Matthews, Ph.D. that AI is overhyped in biotech. She’s all-in, and so are the top brass there. This Bioprocess Online exclusive Q&A with Dr. Matthews sheds light on why Sanofi is committed to becoming the “first pharma company powered by artificial intelligence at scale.” READ NOW →

Tricky Science, Tricky Business

Silence Therapeutics plc President & CEO Craig Tooman was my guest on episode 97 of the Business of Biotech, long before Anna Rose Welch began her encroachment on our RNA-centric episodes. In this column he penned for Cell & Gene, Tooman walks the balance between science and business that Anna Rose and I are constantly wrestling over. READ NOW →

Guidance, Sans Precedent

In case you haven’t gotten enough on RNA and heard enough from Anna Rose (are you seeing the pattern I’m seeing?), here are her Advancing RNA takeaways from the FDA 's Platform Designation Guidance. TL/DR: She says on a scale between “the guidance of our dreams” & “duh,” this particular guidance falls closest to the latter. READ NOW →

AI Beyond Drug Discovery

In keeping with Sanofi ’s headlong dive into AI, the upstart Life Science Connect editor Tyler Menichiello hosted the most recent Bioprocess Online Live event on pragmatic applications for AI/ML in biopharma manufacturing. With the AI-enabled drug discovery drum wearing a little thin, this fresh perspective on expanded applications for the technology is a hot and timely take.

READ NOW →

Quotes Of The Month

“By the second meeting we started talking about starting a company together and then we took that process very seriously. Over a few months we actually did a trial period of working together. We had a date on the calendar where we said by this day, if it doesn't work out, we can say no. No hard feelings.”

― Sophia Lugo , cofounder, Radar Therapeutics , Episode 216

“I said, I know circular RNA, I can recruit Thomas [Hansen, Ph.D.] … and we can build a circular company instead of pursuing these legacy immunotherapy assets.”

― Erik Digman Wiklund , Ph.D., CEO, Circio Holding ASA , Episode 217

“Pharma companies, in the end, are the customers of biotech. We sell the biotech, or the product, to a pharma. That's where 80% or 90% of the companies end up somewhere in their life. So it's good to know your customer.”

― Erik van den Berg , CEO, Memo Therapeutics AG , Episode 218

Advancing RNA | Bioprocess Online | Cell & Gene | Clinical Leader | Drug Delivery | Life Science Leader | Pharmaceutical Online | Outsourced Pharma | Biosimilar Development

© Copyright 2024 Vertmarkets, Inc. 5340 Fryling Rd Suite 100, Erie, PA 16510